Shattuck Labs reported a net loss of $15.2 million ($0.12 per share) for the quarter ended June 30, 2026, compared to a $12.5 million loss in the prior year period. R&D expenses increased to $11.7 million from $8.7 million as the company advances its pipeline. The firm holds approximately $208.3 million in cash and investments, sufficient to fund operations into 2029. Phase 1 data for lead candidate SL-325 showed a favorable safety profile and durable TL1A blockade, supporting an upcoming Phase 2b trial in Crohn's disease expected in Q3 2026. Additionally, the company announced progress on bispecific candidate SL-846 and completed capital raises totaling approximately $143.3 million through public offerings and warrant exercises. Shattuck Labs is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for inflammatory and immune-mediated diseases.

Shattuck Labs, Inc. entered into an underwriting agreement on June 9, 2026, to issue and sell 10,879,376 shares of common stock at $4.00 per share and 7,870,624 pre-funded warrants to purchase common stock at $3.9999 per share. The underwriters, including J.P. Morgan Securities LLC and Leerink Partners LLC, were granted an option to purchase an additional 2,812,500 shares, which they exercised in full on June 10, 2026. The offering is expected to close on June 11, 2026. Shattuck Labs, Inc. is a biotechnology company focused on cannabis-based therapeutics.

Shattuck Labs, Inc. announced Phase 1 clinical trial data for its lead DR3 blocking antibody, SL-325, showing complete DR3 occupancy at doses of 0.1 mg/kg and higher, with a durable, potentially quarterly dosing-compatible subcutaneous formulation. The company expects to initiate the RECEPTIVE-CD1 Phase 2b trial for Crohn's disease in Q3 2026 and submit an IND for its bispecific candidate SL-846 in the first half of 2027. Additionally, approximately 50.6 million warrants were exercised, which is expected to receive the company approximately $49.3 million in additional gross proceeds. Shattuck Labs, Inc. is a biotechnology company focused on developing DR3 blocking antibodies and bispecific antibodies.